Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis
Metrics: PDF 1339 views | HTML 1071 views | ?
Zhan Li1,*, Songcheng Yin2,*, Lei Zhang1, Weiguang Liu1, Bo Chen1
1Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China
2Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China
*These authors contribute equally to this work
Bo Chen, email: email@example.com
Keywords: E-cadherin, breast cancer, prognosis, biomarker, meta-analysis
Received: July 15, 2016 Accepted: January 16, 2017 Published: January 27, 2017
The prognostic value of E-cadherin expression in patients with breast cancer has been studied for years, yet results remain controversial. We thus performed a comprehensive evaluation of the association between E-cadherin expression and prognosis through a meta-analysis. The databases PubMed, Embase and Cochrane Library were searched. A total of 7,353 patients from 33 studies were subject to final analysis. The results showed there was a significant association between reduced expression of E-cadherin and overall survival (OS) (HR 1.79, 95% CI 1.41–2.27) and disease-free survival (DFS) (HR 1.62, 95% CI 1.31–1.99) in breast cancer. Downregulated expression of E-cadherin significantly correlated with tumor histological grade (OR 1.44, 95% CI 1.06–1.96), TNM stage (OR 2.44, 95% CI 1.75–3.41), tumor size (OR 1.38, 95% CI 1.18–1.60), lymph node status (OR 1.55, 95% CI 1.15–2.10), and progesterone receptor status (OR 1.44, 95% CI 1.10–1.88).This meta-analysis suggested that reduced E-cadherin expression might be a predictor of a poorer prognosis and could be a potentially new gene therapy target for breast cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.